Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.

October 4, 2024 | Michael Mack speaks with Stefan Anker about the outcomes and implications of the RESHAPE-HF2 trial.

With a much longer half-life than other radiotracers, flurpiridaz F-18 will boost patient access to PET imaging, one expert ...

While promising, questions remain about sustained long-term benefits of cardiac myosin inhibitors and their impact on ...

In one study, outcomes were similar regardless of baseline LVEF and recent worsening HF emerged as an important indicator.

Indications that the GLP-1 drug has greater benefits in the most frail patients should be viewed cautiously, one expert says.

Most of our top stories this month stemmed from the ESC Congress—a mix of drug and device trials as well as guidelines.

Among the trends in the report are a growing proportion of younger adults with HF and worsening of racial disparities.

Cardia Ltd., a global leader in the development of leaflet modification solutions for treating heart valves, announced today that the United States Food and Drug Administration (FDA) provided market ...

The findings were particularly pronounced in individuals with dementia, pointing to a possible vascular benefit of higher BP.

We've been talking about it for decades, but we haven't seen the progress that we really want to see,” Vijay Kunadian says.

The society says it is discussing virtual options to deliver the educational content to attendees at a later date.